Navigation Links
Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
Date:6/26/2008

sses and multiple levels of government to make Tamiflu more available and accessible to those who may need it in a pandemic. Roche increased global production of Tamiflu more than 15- fold and created a complete supply chain on U.S. soil at the request of HHS. The company has donated more than 5 million treatment courses to the WHO for use as a rapid response at the site of a pandemic outbreak and for its regional stockpiles.

Roche has also sponsored a series of pandemic planning workshops for businesses around the country, creating a forum for multi-sector dialogue. Insights, information and practical tools have been compiled by Roche at http://www.pandemictoolkit.com.

Roche has taken extensive steps to ensure its own business continuity and continued manufacturing of Tamiflu and other life-saving medicines during a pandemic outbreak. Roche has provided Tamiflu to all its employees in the U.S. and globally, along with medical consultation and education about disease prevention and pandemic flu.

To date, Roche U.S. has received inquiries from more than 800 U.S.-based companies, large and small in a variety of industries, with Tamiflu orders from more than 300 companies, in quantities ranging from a few hundred to hundreds of thousands of treatment courses.

For more information, businesses may contact Roche via phone: Pandemic Planning Hotline 888-394-2838, or by e-mail: Nutley.TAMIFLU_Inquiry@Roche.com.

About Tamiflu

Tamiflu, co-developed by Gilead Sciences, Inc., based in Foster City, CA, is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients one year and older who have had flu symptoms for no more than two days. Tamiflu is also indicated for the prevention of influenza in patients one year and older. Tamiflu is not a substitute for annual early vaccination as recommended by the CDC.

Tamiflu was approved based on
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
3. Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
4. Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees
5. Roche Research Director Grace Ju Hailed as NJABR Outstanding Woman of Science
6. MacroChem Acquires Virium Pharmaceuticals
7. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
8. Roche Molecular Diagnostics Invests $57.5 Million in Green Research Building
9. MacroChem Appoints David P. Luci as New CFO
10. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
11. Roche to Acquire Ventana for $89.50 per share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014  Lisa Kulik saw fireworks for the ... holiday, thanks to a groundbreaking retinal implant co-invented by ... clinician-researcher at the University of Southern California (USC) Eye ... Peoria, Ariz. resident who has retinitis pigmentosa, ... sight. On June 2, she became the first person ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
(Date:8/27/2014)... 27, 2014 Research and Markets ... for Pulp & Paper Industry Report 2014" report ... for Pulp & Paper Industry Report 2014 is a ... the global enzyme for pulp & paper industry. ... industry including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Webcast Live on Company,s Website -, TUSTIN, Calif., ... a clinical stage biopharmaceutical,company developing monoclonal antibodies for the ... that senior management will,present at the 10th Annual BIO ... 9:30 am EST. The conference will be held at ...
... 7 Enigma Diagnostics,the life sciences company ... it has signed license agreements with Applera,Corporation., ... include a Real-Time Instrument,Patent License Agreement and ... Enigma with access under patents owned or ...
... Feb. 7 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... Company,s Chief Executive Officer, is scheduled to present ... Mr. Bentsur will present an,overview of the Company ... compound for the treatment of diabetic neuropathic,pain. Mr. ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Enigma Signs Real-Time PCR Licences With Applera 2XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2
(Date:8/27/2014)... be found in both unprocessed and processed foods. Over ... been infected with Listeria from processed food, ... is notoriously difficult to fight because it has an ... surroundings, says Associate Professor Birgitte Kallipolitis, University of Southern ... and Molecular Biology, she has published a study, which ...
(Date:8/27/2014)... State University have found that century-old museum specimens hold clues ... pest that can weaken and kill trees and the ... insect populations increase on oak and maple trees in warmer ... also increase with global warming," says Dr. Elsa Youngsteadt, a ... paper on the work. , "More scale insects would be ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Museum specimens, modern cities show how an insect pest will respond to climate change 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... practice of using earthworms to turn waste ... organic waste management practice. During vermicomposting, earthworms ... aerobic, moist environment. The resulting product, called ... and amateur growers an environmentally friendly alternative ...
... COLLEGE PARK, Md. -- University of Maryland ... software and computational techniques to analyze patterns of ... or other locations and predict the locations of ... support those attacks. University of Maryland computer ...
... has been keeping a secret that may be the key ... Researchers at Rice University and Baylor College of Medicine ... H1N1,s method for evading detection by the immune system. ... the virus,s first known appearance in the deadly "Spanish flu" ...
Cached Biology News:Vermicompost from pig manure grows healthy hibiscus 2'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Study reveals H1N1 unexpected weakness 2
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
MMP-1/8 (H-300)...
PGC-1 (H-300)...
Biology Products: